From Seekingalpha · Equity Eagle · · 40s
Protagonist Therapeutics Turns Biotech into Royalty Compounder
PTGX shifts from biotech to royalty-driven business with FDA-approved drugs and $300M buyback.
In brief
PTGX shifts from biotech to royalty-driven business with FDA-approved drugs and $300M buyback. Protagonist Therapeutics (PTGX) became a royalty compounder after FDA approval of rusfertide as MIMRYLO, generating $605M annual revenue. Originally reported by Seekingalpha.
FDA Approval Shift
Protagonist Therapeutics gained FDA approval for rusfertide as MIMRYLO, triggering $275 million in revenue.
“I last covered Protagonist Therapeutics (PTGX) about four months ago, in June, when rusfertide was still under priority review and the company held roughly $620 million in cash.”
Royalty Model Growth
PTGX secured back-end royalties and milestones from Takeda and J&J, shifting risk to partners while retaining economic upside.
Financial Turnaround
Consensus forward earnings are nearly 4x trailing levels, with high-margin royalty streams generating $605 million annually against $220 million in expenses.
Here's the gist
Protagonist Therapeutics (PTGX) became a royalty compounder after FDA approval of rusfertide as MIMRYLO, generating $605M annual revenue.
